Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, open-label, dose-escalation, multiple dose study of the safety, tolerability, and immune response of CRS-207 in adult subjects with selected advanced solid tumors who have failed or who are not candidates for standard treatment

Next Previous
X
Search
Trial Profile

A phase 1, open-label, dose-escalation, multiple dose study of the safety, tolerability, and immune response of CRS-207 in adult subjects with selected advanced solid tumors who have failed or who are not candidates for standard treatment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRS 207 (Primary)
  • Indications Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 07 Feb 2012 Results were published in Clinical Cancer Research.
    • 18 Apr 2011 Top-line results reported in a Aduro BioTech media release.
    • 15 Jul 2010 Tolerability and preliminary analysis of long-term survival data has been reported in a Aduro Biotech media release. Further results are expected later in 2010.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top